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risks of treatment with alteplase in subgroups of trial patients with warnings and contraindications for thrombolysis. We aim at providing valuable information to simplify and expand future guidelines and licences.
Methods

Data Source and Patients
We collected demographics, clinical data, and functional outcome measures from neuroprotectant trials in ischemic stroke conducted from 1998 to 2008 and held within VISTA. 10 Data were anonymized in relation to patients and trials. We excluded trials that had tested effects of thrombolysis or of any drug now known to influence outcome after stroke, and patients who lacked relevant baseline or outcome information: baseline National Institutes of Health Stroke Score (NIHSS) , age, alteplase administration as standard of care, occurrence of adverse events or serious adverse events (SAE), and modified Rankin Scale (mRS) at day 90.
We collected data from 9613 ischemic stroke patients, of whom 9046 have been enrolled within 6 hours and 567 within 12 hours after symptom onset into a neuroprotectant trial. A total of 8438 out of 9613 (87.8%) were enrolled during a period, and in a country where treatment with intravenous thrombolysis had been approved for use within 3 hours after stroke onset. A total of 2755 out of 8438 (32.6%) were thrombolyzed as per institutional practice at the point of trial conduct. Thrombolyzed patients were on average enrolled in the year 2004 (±2.6 years) and nonthrombolyzed patients in the year 2002 (±3.5 years).
Warnings and Contraindications
We searched the VISTA database for all available variables providing information on warnings and contraindications for treatment with alteplase. We assigned patients as either having or not having each of these, and excluded patients with missing data from analyses of the corresponding variable. Patients can feature in more than 1 subgroup. The definitions of warnings and contraindications available for analysis within VISTA are given in Table 1 . 
IV Antihypertensives Use of intravenous antihypertensives on the day of enrolment ‡ EU-L
CT Findings
Early Changes Edema, dense middle cerebral artery sign, loss of insular ribbon, lenticular hypodensity, acute infarction, sulcal effacement, or ASPECT-score of 8 or 9 § Major Early Changes Mass effect, infarction of >1/3 of the middle cerebral artery territory, midline shift, or ASPECT-score of ≤7 §
Results of all patients were given for reference ASPECT-Score indicates Alberta Stroke Program Early CT-Score; CT, Computer tomograpy; EU-G, European Stroke Organization Guidelines; 11 EU-L, European License; 12 NIHSS, National Institutes of Health Stroke Scale; US-G, American Heart Association/American Stroke Association Guidelines; 13 and US-L, American License.
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Outcome Measures
The primary outcome measure was the distribution of mRS at 90 days using the full scale. 15 The mRS was available for all patients (n=9613). For comparison with prior trials and reports, dichotomized outcomes at 90 days (mRS 0-1, mRS 0-2, NIHSS 0-1, and mortality) were also reported. NIHSS at 90 days was recorded in 8608 patients. Additionally, information on occurrence of intracranial hemorrhages (ICH) within the first 4 days after stroke was retrieved from adverse events and SAE data, as raw computerized tomography (CT) data are available for few trials held within VISTA, and as only thrombolyzed patients received routine follow-up CTs. Although adverse events and SAE reporting was rigorous in the included trials, asymptomatic ICH are likely to be underreported in nonthrombolyzed patients. In approximation to the definition of symptomatic ICH (SICH) used in the second European Cooperative Acute Stroke Study (ECASS II), 4 we report the rates of SICH, defined as any ICH with neurological deterioration, as indicated by an NIHSS increase of ≥4 points from baseline; or any ICH leading to death within 7 days thereafter. As NIHSS was not required to be recorded on every subsequent day, some SICH might be missed by this definition, SICH was additionally defined as any ICH that has been recorded to be the cause of an SAE. As information on exact onset timing of adverse events or SAE is not available for all patients within VISTA, information on occurrence of SICH could only be presented for 7326 patients. However, by analyzing the mRS across the full scale, we take into account any effects of serious bleeding in our primary outcome.
Statistical Analysis
Nonrandomized adjusted comparisons of outcomes were conducted within each subgroup, differentiating patients who received alteplase versus patients who did not (controls). All outcome analyses were adjusted for age and baseline NIHSS, as previously justified. 15 We did not adjust for time to treatment, as this variable was incompletely available. Unadjusted baseline comparisons were conducted using the 2 sample t test, the Mann-Whitney U test, or the χ 2 test depending on the distribution and nature of the data. The primary outcome measure was the mRS at 90 days, analyzed across the whole distribution of scores with the use of the Cochran-Mantel-Haenszel test, with adjustment for stratification variables (age: ≤30, 31-40, 41-50, 51-60, 61-70, 71-80, ≥81; baseline NIHSS: ≤4, 5-8, 9-12, 13-16, 17-20, 21-24, ≥25). Odds ratio (OR) and 95% CI were computed using ordinal logistic regression. Whereas ordinal logistic regression gives an estimate of treatment effect, the Cochran-MantelHaenszel test gives a more conservative probability value based on fewer assumptions. 16 Dichotomized outcome measures were assessed using binary logistic regression. Analyses were undertaken using SAS 9.2.
Results
A total of 4793 out of 9613 patients (49.6%; 1281 thrombolyzed, 3512 nonthrombolyzed) had at least one known contraindication, and 6231 out of 9613 (64.8%; 1946 thrombolyzed, 4285 nonthrombolyzed) had at least one known contraindication or warning for treatment with alteplase. Detailed information about relevant baseline characteristics is given in Table 2 .
Results for our primary outcome measure, distribution of mRS at 90 days, in patients with specified warnings and contraindications for thrombolysis are presented in Figure 1 . Rates of SICH within the first 4 days after stroke are presented in Figure 2 . Additional detailed information about dichotomized outcomes in these subgroups, as well as for all outcomes in subgroups without having specified warnings and contraindications are presented in the online-only Data Supplement.
Discussion Age/Medical History
The present results are consistent with previous analyses of registry data 17, 18 and an updated meta-analysis of thrombolysis trial data, including IST-3, 9 showing that thrombolysis is effective in patients aged >80, at least up to 3 hours after stroke onset.
In an analysis of 5 thrombolysis trials, history of prior stroke and diabetes mellitus was found to be a predictor of poor clinical outcome in patients with AIS treated within 0 to 6 hours. 19 Although alteplase treatment in AIS patients with combined history of prior stroke and diabetes mellitus has not been approved in Europe, 12 subsequent registry analyses showed no statistical justification for the exclusion of these patients from treatment. 20, 21 Corroborating, the present analysis showed a significant benefit from thrombolysis in the Stroke & Diabetes subgroup; note that the present dataset partly overlaps with reports in previous publications, however. 18, 20, 21 22 IST-3 trialists detected no significant effect of treatment with antiplatelets prior to thrombolysis on functional outcome. 23 The primary outcome of the present study corroborates the effectiveness of thrombolysis in the subgroup of patients with Single Antiplatelets, whereas it shows discouraging results in the Dual Antiplatelets subgroup. The rate of SICH in patients with prior Dual Antiplatelets was the highest among all patients receiving thrombolysis, but with small numbers of patients remains statistically indistinguishable from the control group. A prior study also found no association between prior antiplatelet use and the likelihood of recanalization and good outcomes. 24 Although the European and American licences exclude AIS patients with prior anticoagulation from alteplase treatment, 12, 14 the American Heart Association/American Stroke Association guidelines relaxed this restriction by recommending treatment with alteplase if oral anticoagulation has been taken, but the International Normalized Ratio (INR) is below 1.7. 13 Additionally, the AHA/ASA guidelines recommend not to delay initiation of treatment with alteplase by waiting for blood and coagulation tests in patients without suspected bleeding abnormality. Only limited and partly contradictory data are Figure 1 . Odds of more favorable outcome for thrombolyzed patients compared with controls, adjusted for age, and baseline National Institutes of Health Stroke Scale (NIHSS), within subgroups of patients with specified warnings and contraindications. Number of thrombolyzed (intravenous alteplase) and control patients within these subgroups is presented on the left. Odds ratio (OR) with 95% confidence interval (95% CI) and Cochran-Mantel-Haenszel (CMH) test probability values are presented in the middle. As multivariate ordinal logistic regression uses a different algorithm to the adjusted CMH test, a discrepancy between 95% CI and CMH probability value of 0.05 can occur. The CMH probability value was prespecified as our primary measure of significance. The unadjusted modified Rankin Scale (mRS) distribution at 90 days in controls (top) and treated patients (bottom) within each subgroup is presented on the right. Platelets <100
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Major Early Changes ASPECT ≤7
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available on this subject. 8, 25, 26 Although in most subgroups of patients with disturbed hemostasis, rates of SICH were higher in thrombolyzed patients (eg, OAC), OR point estimates for our primary outcome measure favored alteplase treatment. Cochran-Mantel-Haenszel estimates were significant for benefit in patients with OAC & INR ≤1.7 and APTT >39. These results may have implications for trials adding further antithrombotic drugs to intravenous thrombolysis to improve clot lysis, in that combinations of thrombolysis with anticoagulants may prove safer than combining with potent antiplatelet agents. This is relevant with the ongoing Argatroban+Alteplase and CLEARER (Eptifibatide+Alteplase) studies.
Glucose/Blood Pressure
Previous analyses have reported significantly increased rates of SICH in thrombolyzed stroke patients with only mildly elevated baseline glucose levels. 27, 28 Although the rate of SICH was slightly increased in our subgroup of patients with Glucose >180, functional outcome significantly favored treatment with alteplase. Subgroups of patients with Glucose >400 and <40 were small, but none of these patients treated with alteplase experienced a SICH.
High initial systolic blood pressure was found to predict less benefit from thrombolysis in an analysis of 5 thrombolysis trials. 19 Although OR in our primary analysis of subgroups with BPSYS ≥185, BPDIA ≥110, and IV Antihypertensives significantly favored alteplase treatment, rates of SICH were increased in thrombolyzed patients. Thus, caution should be exercised, as violations of pretreatment blood pressure parameters are associated with an increased risk of bleeding.
29
CT Findings
Analyses of baseline imaging data from NINDS showed that early ischemic changes were not associated with increased risk of adverse outcome, 30 whereas observational data has suggested increased risk of SICH with early imaging findings. 27 IST-3 trialists found no significant association of recent ischemic changes at randomization with benefit from thrombolysis. 23 Accordingly, present analyses in subgroups of patients with CT Findings favored thrombolysis treatment, despite marginally increased risk of SICH.
NIHSS
A pooled analysis of 6 thrombolysis trials showed no evidence to exclude AIS patients from treatment based on their initial NIHSS. 31 The IST-3 trialists observed a significant trend for greater benefit from thrombolysis, with increasingly severe strokes. 23 Interaction tests in the subgroups of IST3 patients should be interpreted with caution, as overall benefit for their primary outcome was nonsignificant. Although in the present study a clear benefit for thrombolysis in patients with NIHSS >22 is evident, benefit was not confirmed in the subgroup of patients with NIHSS <6. However, the size of the latter subgroup was small, leaving residual uncertainty. 
General
The present retrospective analysis shows a broad trend of more favorable outcome, as well as lower mortality associated with alteplase treatment across all subgroups of patients. Our analysis was based on observational rather than trial data. Thus, selection bias is inevitable. Additionally, the general standard of care may have been different in patients receiving alteplase than in controls, as time of enrolment differed on average by 2 years and information on duration of stroke unit care is not available within VISTA. Nevertheless, all patients were participants in clinical trials and thereby received similar attention and a careful follow-up. The presented patient population may have had a better baseline functional status prior to stroke than the general stroke population encountered in clinical practice, but in this respect, they will be comparable with thrombolysis trial patients. Although early complications are rare after thrombolysis, and although the delay between initiating alteplase and enrolment in the VISTA trials was generally short, there is a possibility that a few patients with contraindications who suffered early complications could have been excluded from enrolment, and thus from our sample, leading to underestimation of the complication rate. It is also possible that early improvers were excluded, with an opposite effect.
However, randomized controlled trials are simply not feasible for many of the subgroups analyzed here, so these data provide valuable guidance on the risks and benefits of thrombolysis in numerous subgroups of patients, where equipoise exists and guidelines and treatment practices vary. Many of the warnings and contraindications of alteplase may not be justified and licences, guidelines, and protocols should be adjusted to accommodate recent data from registries and real-world experience.
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Figures for subgroups of patients with specific contraindications or warnings Figure1 MRS 0 to 1 at 90 days
Odds of having a mRS at 90 days of 0 or 1 for thrombolysed patients compared to controls, adjusted for age and baseline NIHSS, within subgroups of patients with specified warnings and contraindications. Number of treated (Alteplase) and control patients within these subgroups with available outcome information is presented on the left. Odds ratio (OR) with 95% confidence interval (95% CI) and p-value are presented on the right. NA = not applicable
Figure4 Mortality at 90 days
Odds of mortality at 90 days for thrombolysed patients compared to controls, adjusted for age and baseline NIHSS, within subgroups of patients with specified warnings and contraindications. Number of treated (Alteplase) and control patients within these subgroups with available outcome information is presented on the left. Odds ratio (OR) with 95% confidence interval (95% CI) and p-value are presented on the right. NA = not applicable
Figures for subgroups of patients without specific contraindications or warnings
Figure6 ordinal MRS at 90 days
Odds of more favourable outcome for thrombolysed patients compared to controls, adjusted for age and baseline NIHSS, within subgroups of patients without specified warnings and contraindications. Number of thrombolysed (Alteplase) and control patients within these subgroups is presented on the left. Odds ratio (OR) with 95% confidence interval (95% CI) and Cochran-Mantel-Haenszel (CMH) test p-value are presented in the middle. The unadjusted mRS distribution at 90 days in controls (top) and treated patients (bottom) within each subgroup is presented on the right.
